ifosfamide
ifosfamide: 23 clinical trials tracked.
ifosfamide evidence translation
What we can confirm
23 tracked trials
What it means
What to watch
Prepared research question
What is verified about ifosfamide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 6 study sponsors
Related indications
Clinical Trials (23)showing 10 most recent
A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Primary endpoint: Number of Cohort 1 participants with relapse free survival (RFS) during study
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Primary endpoint: Feasibility and Safety - Consolidation
Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Primary endpoint: Time to event-free survival (EFS) post-Consolidation I (C1)
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
Primary endpoint: Objective response
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas
Primary endpoint: Determination of the safety and technical feasibility of microdevice insertion/removal, as assessed by adverse events by CTCAE 5.0.
N10: Reduced Therapy for High-Risk Neuroblastoma
Primary endpoint: Evaluate participant response
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Primary endpoint: Treatment Arm I: BsAb: Occurrence of an objective response (OR)
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Primary endpoint: Event-free survival (EFS)
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)
Primary endpoint: Event-free survival (EFS) as assessed by independent central review (ICR)
Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas
Primary endpoint: Assessment of the antitumor activity of retifanlimab when prescribed in association with neoadjuvant chemotherapy (doxorubicin+ifosfamide)